{"PubmedArticle": [{"MedlineCitation": {"SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "OtherAbstract": [], "CitationSubset": ["IM"], "KeywordList": [], "GeneralNote": [], "PMID": "17583205", "DateCompleted": {"Year": "2008", "Month": "05", "Day": "09"}, "DateRevised": {"Year": "2023", "Month": "12", "Day": "13"}, "Article": {"ArticleDate": [], "Language": ["chi"], "ELocationID": [], "Journal": {"ISSN": "1001-5302", "JournalIssue": {"Volume": "32", "Issue": "7", "PubDate": {"Year": "2007", "Month": "Apr"}}, "Title": "Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica", "ISOAbbreviation": "Zhongguo Zhong Yao Za Zhi"}, "ArticleTitle": "[Experimental study on treating hyperlipidemic fatty liver with Taizhi'an capsule].", "Pagination": {"StartPage": "616", "EndPage": "619", "MedlinePgn": "616-9"}, "Abstract": {"AbstractText": ["To observe the effects of Taizhi'an capsule in treatment of hyperlipidemic fatty liver.", "The model rats were induced by feeding high caloric diet for 8 weeks, then fifty rats were randomly divided into five groups, and each group had ten rats, the Taizhi'an groups (high dose 1 000 mg x kg(-1), middle dose 500 mg x kg(-1), low dose 250 mg x kg(-1)), the Yishanfu group and the model group. Liver index (liver weight/body weight), liver function, blood lipid, liver lipid, the content of MDA and SOD in liver were assayed after therapy, and observe Pathologic changes in rats liver.", "Liver index, blood lipid, liver lipid, liver function increased significantly (P < 0.001) in model rats, and the content of SOD in liver decreased significantly (P < 0.05), Liver histology expressed mild to moderate fat denaturation; After being treated with high and middle dose of Taizhi'an capsule for six weeks, blood lipid, liver function decreased significantly (P < 0.001), and liver lipid decreased significantly (P < 0.001, P <0.05), the content of SOD in liver increased significantly (P < 0.05), meanwhile liver histology was closed to normal.", "Taizhian capsule is effective in the treatment of hyperlipidemic induced fatty liver."]}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "Second Affiliated Hospital Zhejiang University College of Medicine, Hangzhou 310009, China."}], "Identifier": [], "LastName": "Sun", "ForeName": "Mei", "Initials": "M"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Shan", "ForeName": "Jian-Zhen", "Initials": "JZ"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Zhang", "ForeName": "Guo-Ping", "Initials": "GP"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Ying", "ForeName": "Hua-Zhong", "Initials": "HZ"}], "PublicationTypeList": ["English Abstract", "Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "China", "MedlineTA": "Zhongguo Zhong Yao Za Zhi", "NlmUniqueID": "8913656", "ISSNLinking": "1001-5302"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Capsules"}, {"RegistryNumber": "0", "NameOfSubstance": "Drugs, Chinese Herbal"}, {"RegistryNumber": "0", "NameOfSubstance": "Triglycerides"}, {"RegistryNumber": "0", "NameOfSubstance": "Triterpenes"}, {"RegistryNumber": "0", "NameOfSubstance": "taizhi'an"}, {"RegistryNumber": "4Y8F71G49Q", "NameOfSubstance": "Malondialdehyde"}, {"RegistryNumber": "97C5T2UQ7J", "NameOfSubstance": "Cholesterol"}, {"RegistryNumber": "EC 1.15.1.1", "NameOfSubstance": "Superoxide Dismutase"}, {"RegistryNumber": "EC 2.6.1.1", "NameOfSubstance": "Aspartate Aminotransferases"}, {"RegistryNumber": "EC 2.6.1.2", "NameOfSubstance": "Alanine Transaminase"}], "MeshHeadingList": [{"QualifierName": ["blood"], "DescriptorName": "Alanine Transaminase"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["blood"], "DescriptorName": "Aspartate Aminotransferases"}, {"QualifierName": [], "DescriptorName": "Capsules"}, {"QualifierName": ["blood", "metabolism"], "DescriptorName": "Cholesterol"}, {"QualifierName": ["administration & dosage", "pharmacology"], "DescriptorName": "Drugs, Chinese Herbal"}, {"QualifierName": ["drug therapy", "etiology", "metabolism"], "DescriptorName": "Fatty Liver"}, {"QualifierName": ["complications"], "DescriptorName": "Hyperlipidemias"}, {"QualifierName": ["chemistry"], "DescriptorName": "Ligustrum"}, {"QualifierName": ["drug effects", "metabolism", "pathology"], "DescriptorName": "Liver"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": ["metabolism"], "DescriptorName": "Malondialdehyde"}, {"QualifierName": [], "DescriptorName": "Phytotherapy"}, {"QualifierName": ["chemistry"], "DescriptorName": "Plant Leaves"}, {"QualifierName": ["chemistry"], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": [], "DescriptorName": "Random Allocation"}, {"QualifierName": [], "DescriptorName": "Rats"}, {"QualifierName": [], "DescriptorName": "Rats, Sprague-Dawley"}, {"QualifierName": ["metabolism"], "DescriptorName": "Superoxide Dismutase"}, {"QualifierName": ["blood", "metabolism"], "DescriptorName": "Triglycerides"}, {"QualifierName": ["administration & dosage", "pharmacology"], "DescriptorName": "Triterpenes"}, {"QualifierName": [], "DescriptorName": "Ursolic Acid"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2007", "Month": "6", "Day": "23", "Hour": "9", "Minute": "0"}, {"Year": "2008", "Month": "5", "Day": "10", "Hour": "9", "Minute": "0"}, {"Year": "2007", "Month": "6", "Day": "23", "Hour": "9", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["17583205"]}}], "PubmedBookArticle": []}